Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Oncolys BioPharma's Days Inventory for the
three
months ended in Dec. 2025 is calculated as:
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Oncolys BioPharma's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.
Oncolys BioPharma Inventory Turnover Related Terms
Oncolys BioPharma Inventory Turnover Historical Data
* Premium members only.
The historical data trend for Oncolys BioPharma's Inventory Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncolys BioPharma (TSE:4588) has a Inventory Turnover of 0.00 as of Dec. 2025. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Oncolys BioPharma and its competitors.
Is Oncolys BioPharma's Inventory Turnover too high?
Oncolys BioPharma's current Inventory Turnover is 0.00. Overall, Oncolys BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncolys BioPharma's Inventory Turnover compare to VRTX and REGN?
Oncolys BioPharma's Inventory Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Biotechnology company?
A good Inventory Turnover depends on the Biotechnology industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on Oncolys BioPharma and its competitors. Oncolys BioPharma's current Inventory Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolys BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Oncolys BioPharma (TSE:4588) is currently considered Significantly Overvalued. The stock's GF Value™ is 円361.55, compared to a current price of 円2,487.00 — trading 587.9% above its estimated fair value. The current Inventory Turnover is 0.00. Oncolys BioPharma's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For Oncolys BioPharma (TSE:4588), the current Inventory Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncolys BioPharma (TSE:4588) Overvalued in 2026?
Based on GuruFocus' analysis, Oncolys BioPharma stock appears to be overvalued.
The current stock price of 円2,487.00 is trading 587.9% above its estimated GF Value™ of 円361.55.
GuruFocus considers Oncolys BioPharma to be Significantly Overvalued.
Key valuation signals for TSE:4588:
Inventory Turnover: 0.00
GF Value™: 円361.55 vs. price of 円2,487.00 (587.9% above fair value)
No single metric tells the full story. See the TSE:4588 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncolys BioPharma Inc develops pharmaceutical products. The company is a biopharmaceutical company focused on developing therapies for cancer treatment. Their product pipeline includes various drug candidates such as Telomelysin (OBP-301) and OBP-702, aimed at addressing unmet medical needs in oncology. The company targets healthcare providers and institutions involved in cancer care and research.
40GF Score
Get the complete analysis for TSE:4588
Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4588 has been successfully added to your 
